1. Introduction {#s0005}
===============

The first case of Novel coronavirus disease 2019 (COVID-19) was detected in Wuhan, China, in late December, that broke out worldwide, affecting over 227 countries and caused approximately three lakhs deaths till date (<https://www.worldometers.info/coronavirus/> accessed on 13/05/2020). The mortality rate remained 14.50% worldwide (<https://www.worldometers.info/coronavirus/> accessed on 13/05/2020). World Health Organisation had declared COVID-19 as pandemic disease (<http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic>). As of today (13/05/2020), the United States of America contributed the highest number of infected cases and death due to COVID-19 in comparison to other populations (<https://www.worldometers.info/coronavirus/> accessed on 13/05/2020). COVID-19 infection displays a wide range of clinical manifestations. A recent study [@b0005] highlighted cough, sputum production, diarrhoea, nausea/vomiting, and shortness of breath as more frequent clinical phenotypes in critical/non-survived COVID-19 patients, and in contrast, fever and headache were less prevalent. Furthermore, the pathogenesis of the diseases is regulated by several host factors. Various biomolecules such as aspartate aminotransferase, creatinine, high-sensitive cardiac troponin, procalcitonin, lactate dehydrogenase, and D-dimer has been increased in COVID-19 critical patients in comparison to those with non-severe infected cases [@b0005].

The upregulation of C reactive protein (CRP) has been reported during severe acute respiratory syndrome (SARS) outbreak in 2002 and associated with respiratory dysfunctions and death of the patients [@b0010]. Based on these observations, various studies were carried out in COVID-19 patients hypothesizing CRP as one of the possible biomolecules linked with the death of the infected patients. However, the observations of the reports remained contradictory.

2. Materials and methods {#s0010}
========================

2.1. Literature search strategy {#s0015}
-------------------------------

Two authors, RKK and BRS searched various databases (Medline, ScienceDirect, and Scopus) to trace eligible studies for the present meta-analysis. The keywords used for the search were "COVID-19, coronavirus 2019, 2019-nCoV, SARS-CoV-2, CRP, C-reactive protein, survivors, non-survivors, death, (till 10th May 2020). The title and abstracts of the articles obtained were screened, and apposite papers were downloaded. Furthermore, various preprint servers (bioRxiv, medRxiv and SSRN) were also screened with the above-mentioned keywords.

2.2. Inclusion and exclusion criteria {#s0020}
-------------------------------------

Various inclusion and exclusion criteria were considered in the present investigation. Inclusion of a report in the current meta-analysis must have a) added analysis for death and survivors, b) plasma/serum CRP concentrations, c) data must be presented in mean ± standard deviation (S.D) or median (interquartile range). Exclusion of the articles was based on the following conditions: a) duplicate articles, b) research articles, including only survivors or death cases, c) lack of CRP concentrations data d) review article, summaries, or case report.

2.3. Data extraction {#s0025}
--------------------

Two authors BRS and AP extracted data such as authors\' details, years of publication, population, number of COVID-19 infected subjects, death and survivors, CRP concentrations in mean ± S.D. or median (interquartile range), significance value. Details are shown in [Table 1](#t0005){ref-type="table"} .Table 1Details of studies enrolled in the meta-analysis.Authors, yDigital Object Identifier/ PMIDCountryNumber of COVID-19 patientsSurvivorsNon-survivorsP-valueNumberCRP (mg/L) mean ± S.D./ median (IQR)Mean ± S.D.NumberCRP (mg/L) mean ± SD/median (IQR)Mean ± S.D.Chen Tao et al. 2020 [@b0045]https://doi.org//10.1136/bmj.m1091China27416126.2 (8.7--55.2)30.03 ± 34.78113113 (69.1--168.4)116.83 ± 74.56\<0.001Deng Yan et al. 2020 [@b0020]https://doi.org//10.1097/CM9.0000000000000824China2251163.22 (1.04--21.8)8.68 ± 15.58109109.25 (35--170.28)104.84 ± 101.63\<0.001He Wenjuan et al. 2020 [@b0050]https://doi.org//10.1038/s41375-020-0836-7China135121 (37--144)100.66 ± 107.60868 (64--115)82.33 ± 45.56NSLi Jingwen et al. 2020 (Preprint) [@b0055]https://doi.org//10.2139/ssrn.3546043China161968.48 (0.13--310.10)106.23 ± 233.306581.2 (8.4--284.4)124.66 ± 209.250.00Luo Xiaomin et al.2020 (Preprint) [@b0060]https://doi.org//10.1101/2020.03.21.20040360China2982149.65 (5--37.9)17.51 ± 24.5584100 (60.7--179.4)113.36 ± 89.530.000Ruan Qiurong et al. 2020 [@b0065]https://doi.org//10.1007/s00134-020-06028-zChina1508234.1 ± 54.5--68126.6 ± 106.3--\<0.001Tomlins Jennifer et al. 2020 [@b0070]https://doi.org//10.1016/j.jinf.2020.04.020UK9572^\$^36 (14--67)39 ± 40.092077 (53--124)84.66 ± 56.640.001Tu Wen-Jun et al. 2020 [@b0075]https://doi.org//10.1007/s00134-020-06023-4China17414922 (6--45)24.33 ± 29.1925118 (22--184)108 ± 127.35\<0.001Wang Kun et al. 2020^a^[@b0080]https://doi.org//10.1093/cid/ciaa538China29627711.4 (2.2--27.9)13.83 ± 19.171988.6 (59.7--118.0)88.76 ± 43.49\<0.001Wang Kun et al. 2020^b^[@b0080]https://doi.org//10.1093/cid/ciaa538China443039.9 (11.9--68.1)39.96 ± 43.741498.0 (85.5--117.883.86 ± 14.33\<0.001Wang Lang et al. 2020 [@b0085]https://doi.org//10.1016/j.jinf.2020.03.019China33927444.2 (13.5--82.2)13.83 ± 19.1565102.0 (58.9--187.4)116.1 ± 97.42\<0.001Wang Yang et al. 2020 [@b0090]https://doi.org//10.1164/rccm.202003-0736LEChina34421128 (6--67)33.66 ± 45.53133101 (61--153)105 ± 68.95\<0.001Wu Chaomin et al. 2020 [@b0095]https://doi.org//10.1001/jamainternmed.2020.0994China844069.20 (26.60--120.80)72.2 ± 72.434490.85 (44.55 - \>160)98.43 ± 88.56NSYan Yongli et al. 2020 \^ [@b0100]https://doi.org//10.1136/bmjdrc-2020-001343China48913 (1--48)20.66 ± 41.103997.2 (64.4--191.0)117.53 ± 97.43\<0.001Zangrillo Alberto et al. 2020^\#^[@b0105]•32353223Italy7356180.3 (110.2--255.5)182 ± 110.5617256.4 (144.2--375.4)258.66 ± 186.89NSZhang Jingping et al. 2020 [@b0110]https://doi.org//10.1007/s10389-020-01291-2China191186.9 (47.9--120.5)85.1 ± 61.588166.15 (82.3--129.4)125.95 ± 42.08NSZhang Jun et al. 2020 [@b0115]https://doi.org//10.1016/j.jcv.2020.104392China111937.93 (3.14--22.50)11.19 ± 14.571879.52 (61.25--102.98)81.25 ± 33.57\<0.001[^1]

2.4. Statistical analysis {#s0030}
-------------------------

The meta-analysis was performed by comprehensive meta-analysis V3.1 software (Biostat). Begg's funnel plot and Eggers linear regression analysis were employed to test publication bias. CRP data was available in the median (interquartile range) format in most of the included reports, and those were converted into mean ± standard deviation according to an earlier report [@b0015]. Association of CRP concentrations with COVID-19 disease prognosis was analyzed, and the combined standard difference in means and P-values were calculated. The Q test and I^2^ statistics evaluated heterogeneity among included reports. Based on the results of heterogeneity statistics, random (heterogeneous), or fixed model (non-heterogenous) were deployed for analysis. Furthermore, a sensitivity analysis was performed to test the robustness of the meta-analysis.

3. Results and discussion {#s0035}
=========================

A total of 122 and 153 articles were obtained after searching PubMed and Scopus, respectively. After screening the titles, abstracts, and full text based on inclusion and exclusion criterias, 14 articles, including data of 15 different cohorts were enrolled for the present analysis. Further, we found two articles related to our searched norms from preprint servers. Baseline data from all eligible publications were extracted and presented in [Table 1](#t0005){ref-type="table"}. CRP data in median (interquartile range) were converted into the required format of CMA V3.1 software (mean ± S.D and sample number)[@b0015].

Both Egger's regression analysis (intercept = 0.04, 95% confidence interval = -5.48 to 5.58 and P = 0.98) and Begg's funnel plot (Supplementary Fig.-1) revealed absence of publication bias in the studied reports. Further, significance heterogeneity across enrolled studies was observed (Q = 252.03, P~heterogeneity~ = 0.000, I^2^ = 93.65), suggesting a random model as an appropriate model for testing of association between CRP concentrations and mortality from COVID-19 infection.

The result of the meta-analysis is shown in [Fig. 1](#f0005){ref-type="fig"} . Patients, who died of COVID-19 infections, displayed significantly higher CRP concentrations compared to the survivors (P = 0.000, the standard difference in means = 1.371). Sensitivity analysis by the exclusion of a study each time demonstrated a significant association of CRP with mortality, further strengthen the observation of the present analysis (Supplementary Fig.-2). CRP is an acute-phase protein responsible for the clearance of pathogens through the complement system and enhanced phagocytosis. The most common complications in non-survivors COVID-19 infected patients include acute respiratory distress syndrome, acute cardiac injury, acute kidney injury, shock, disseminated intravascular coagulation, and a significant alterations in CRP level have been observed in these subjects [@b0020]. A positive correlation between CRP concentrations with the lung lesion in COVID-19 infected patients has been demonstrated [@b0010]. Furthermore, the induction of acute kidney damage [@b0025] and the extent of the cardiac injury [@b0030] has been directly linked with the CRP concentrations. Possibly for clearance of viral infections, immune system responded more vigorously by producing various immune molecules and production of CRP [@b0035] beyond threshold limit may lead to dysfunction of various organ system in COVID-19 infected patients. Production of CRP is controlled by genetic makeup of the subject [@b0040] and it would be interesting to investigate candidate genetic approach in different populations to obtain firm conclusion. The results of the present analysis and earlier observations altogether highlighted the importance of CRP as a possible biomarker for mortality by COVID-19 infection. However, more studies are required in different populations to validate the findings of the present report.Fig. 1Forest plot of the association between C-reactive protein and survival status of COVID-19 infected patients. Data from earlier published articles were analyzed in Comprehensive meta-analysis software.
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[^1]: NOTE: mean ± S.D. was calculated by Wan's method, ^\$^CRP was not measured in three samples, \^ with diabetes patients, \# mg/dl, ^a^ training cohort, ^b^ validation cohort.
